Project Grant R44DK118981

The National Institute of General Medical Sciences (NIGMS) awarded a $467,947 Project Grant to the University of Colorado-Denver under CFDA 93.859 (Biomedical Research and Research Training program) to create bioinformatics tools that facilitate identifying genetic variants contributing to adverse drug reactions (ADRs). The key products to be delivered include: 1) A protein docking server to assess how drug variants could cause potential side effects, and 2) Online tools to identify specific...

Amdx Prognostx Inc. received a $791,145 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases within the Department of Health and Human Services. The award falls under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), which promotes biomedical research to improve understanding and treatment of diabetes, digestive, and kidney diseases. Under this award, Amdx Prognostx will develop an enzyme-linked immunosorbent assay...

This $728,513 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a renal quantitative susceptibility mapping (QSM) technique for reliable detection and quantification of hemorrhagic cysts as a prognostic biomarker of kidney function decline in autosomal dominant polycystic kidney disease (ADPKD). The key objective is to leverage QSM...

This Project Grant award of $306,873 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) aims to develop an AI-driven automated system for accurately generating Banff lesion scores from kidney biopsy slides. The project, titled "BANFF-AID: BANFF Automated Nephrology Feature Framework - Artificial Intelligence Diagnosis", will create custom AI models to extract...

Federal Project Grant Award Summary Angiotensin Therapeutics Inc. received a $591,488 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective September 15, 2025, with completion targeted for August 31, 2026. The award funds preclinical research and development of AGT001, a bioengineered soluble Angiotensin-Converting-Enzyme 2 (ACE2) therapeutic...

SGLT2 Inhibitors After Acute Kidney Injury Research Project The University of Minnesota, through its Office of Sponsored Projects Administration, received a $166,953 Project Grant award dated July 15, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports a pilot, pragmatic, cluster-randomized clinical trial (RCT) led by Dr. Daniel Murphy to evaluate...

Federal Project Grant Award Summary Angiotensin Therapeutics Inc. received a $314,355 Project Grant award dated September 15, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop therapeutic solutions for delayed graft function (DGF) in kidney transplantation. The research focuses on AGT001, a bioengineered soluble ACE2 (Angiotensin Converting Enzyme 2)...

This Project Grant award of $306,872.00 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), aims to develop a new 3D shape matching methodology that accounts for water molecules when comparing ligands during drug discovery. The key products and services to be delivered include: Adapting an existing algorithm (WATGEN) to predict water positions in unbound proteins and protein-ligand complexes, and calculate...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) totals $167,768 and aims to evaluate whether beta-lactam antibiotics increase the risk of acute kidney injury (AKI) in patients receiving immune checkpoint inhibitor (ICI) cancer treatments, compared to fluoroquinolone antibiotics. The award will support a target trial emulation study to assess this...

Federal Project Grant Award Summary Award Details: Regennova, Inc., a small disadvantaged business located in Durham, North Carolina, received a Project Grant award of $349,325 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award, issued on August 1, 2025, with completion anticipated by July 31, 2027, supports the development of a therapeutic drug candidate...